PR Newswire Clinical TrialsOriginal article
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
PartnershipPositive
AI Analysis
Summary
VolitionRx reported 112% H1 revenue growth and announced newly formed collaborations and active licensing discussions with over a dozen global diagnostic leaders, advancing toward a $5 million veterinary milestone across its $27+ billion addressable markets.
Financial Highlights
Revenue
112% H1 revenue growth
Outcome Details
Newly announced collaboration and active licensing discussions with more than a dozen global diagnostic leaders
Importance:6/10
Sentiment:
0.70
commercial_momentumpartnershiplicensingveterinarydiagnosticsrevenue_growth
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 26, 2026 1:17 PM